Selective Covalent Inhibitors of Caspase-6

Tech ID: 31809 / UC Case 2020-084-1

Invention Novelty

Caspase 6 (Casp6) has been implicated in several neurodegenerative conditions, including Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease. Casp6 activation has been observed during all stages of Alzheimer’s disease making it an attractive therapeutic target for neurological indications. The current invention identifies a family of covalent small molecules that selectively bind Casp6 over other caspases.

Value Proposition

In 2018, the global market for neurodegenerative disease drugs was valued at over US$35 billion, and projected to exceed US$62 billion by 2026. While a known target in neurodegenerative disease, historically, caspases in general and Casp6 in particular have proven difficult to drug, with previously available inhibitors showing little specificity between the different caspase family members. UCSF investigators have identified small molecule covalent inhibitors that demonstrate good selectivity for Casp6 over other family members.  These compounds can be developed as:

  • Therapeutic agents to treat a wide range of neurodegenerative diseases
  • Imaging agents to diagnose neurodegenerative diseases

Looking for Partners

To develop & commercialize the technology for all clinical applications.

Stage of Development

Pre-Clinical

Data Availability

Under CDA / NDA

Patent Status

Patent Pending

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Keywords

Neurodegenerative disease, small molecules

Categorized As